1. To test our first hypothesis, we measured blood pressure (BP) and plasma MBG in young (3-mo old) and aged (24-mo old) Sprague-Dawley rats, and in aged rats determined the effect of immunoneutralization of MBG on the expression of pro-fibrotic genes in left ventricular (LV) myocardium. One week following a single administration to aged rats of an anti-MBG monoclonal antibody (n=6) or vehicle (n=6), the expression of genes and levels of proteins implicated in pro-fibrotic signaling were assessed in LV myocardium by qPCR analysis. BP did not change, and plasma MBG levels were elevated two-fold (P<0.05) in aged vs. young rats, and was accompanied by upregulation of genes implicated in TGF-signaling: TGF1 - 3-fold;CTGF1 - 6-fold;SMAD3 - 2-fold;collagen-1 - 2.6-fold. Expression of these genes was significantly suppressed following immunoneutralization of MBG in aged rats, although their expression remained higher than in young controls. The expression of a nuclear transcription factor Fli-1, a negative regulator of collagen-1 synthesis, was reduced by 3-fold in aged vs. young rats, and anti-MBG antibody restored levels of Fli-1 in aged rats to the level in young controls. Thus, the age-associated increase in MBG participates in pro-fibrotic signaling linked to advancing age, and cross-talk between TGF-dependent and Fli-1-dependent pro-fibrotic pathways, underlies this MBG effect. 2. To test the second hypothesis, we measured blood pressure (BP), PWV, plasma MBG, and erythrocyte NKA in seven middle-age control subjects and in eight age-matching RH patients treated with lisinopril / amlodipine / hydrochlorothiazide (LAH), before and after addition of spironolactone (50 mg/day) to the LAH regimen for six months. Prior to the addition of spironolactone to the LAH regimen, plasma MBG, BP, and PWV were higher, and NKA activity was reduced in RH patients vs. controls (Table). Addition of spironolactone to conventional triple (LAH) therapy for RH reduced BP and PWV, and reversed erythrocyte NKA inhibition in the absence of an effect on plasma MBG. Thus, aldosterone antagonists reversed MBG-induced NKA inhibition and reduced PWV and BP in patients with RH. These beneficial effects of aldosterone antagonists may, in part, be linked to a concomitant reduction in arterial fibrosis. Table: ------------------------------------------------------------------------------------------ .............................Controls..........RH baseline........RH after spironolactone treatment ------------------------------------------------------------------------------------------ Age (years).................50+/-3..............55 +/- 2...............55 +/- 2 Plasma MBG (nmol/L)......................0.24+/-0.03.......0.42+/-0.07*.........0.53 +/- 0.05** Erythrocyte NKA (micromolPi/mL/hr).......2.8 +/- 0.2........1.9 +/- 0.2**.........2.3 +/- 0.2 # PWV (m/sec)...............6.3 +/- 0.6........8.9 +/- 0.3**.........8.4 +/- 0.2 # 24-hour SBP (mmHg).......................125 +/- 2..........149 +/- 3**...........142 +/- 2 # 24-hour DBP (mmHg).......................75 +/- 2.............95 +/- 2**..............86 +/- 2 # ------------------------------------------------------------------------------------------- Mean+/- SE;*-P<0.05;**-P<0.01 vs. controls, # -P<0.01 vs. baseline RH (ANOVA)

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIAAG000868-06
Application #
8736638
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
2013
Total Cost
$418,343
Indirect Cost
Name
National Institute on Aging
Department
Type
DUNS #
City
State
Country
Zip Code
Fedorova, Olga V; Emelianov, Igor V; Bagrov, Konstantin A et al. (2015) Marinobufagenin-induced vascular fibrosis is a likely target for mineralocorticoid antagonists. J Hypertens 33:1602-10
Grigorova, Yulia N; Juhasz, Ondrej; Zernetkina, Valentina et al. (2015) Aortic Fibrosis, Induced by High Salt Intake in the Absence of Hypertensive Response, Is Reduced by a Monoclonal Antibody to Marinobufagenin. Am J Hypertens :
Fedorova, Olga V; Zernetkina, Valentina I; Shilova, Victoria Y et al. (2015) Synthesis of an Endogenous Steroidal Na Pump Inhibitor Marinobufagenin, Implicated in Human Cardiovascular Diseases, Is Initiated by CYP27A1 via Bile Acid Pathway. Circ Cardiovasc Genet 8:736-45
Fedorova, Olga V; Lakatta, Edward G; Bagrov, Alexei Y et al. (2015) Plasma level of the endogenous sodium pump ligand marinobufagenin is related to the salt-sensitivity in men. J Hypertens 33:534-41; discussion 541
Kennedy, David J; Shrestha, Kevin; Sheehey, Brendan et al. (2015) Elevated Plasma Marinobufagenin, An Endogenous Cardiotonic Steroid, Is Associated With Right Ventricular Dysfunction and Nitrative Stress in Heart Failure. Circ Heart Fail 8:1068-76
Jablonski, Kristen L; Fedorova, Olga V; Racine, Matthew L et al. (2013) Dietary sodium restriction and association with urinary marinobufagenin, blood pressure, and aortic stiffness. Clin J Am Soc Nephrol 8:1952-9
Fedorova, Olga V; Kashkin, Vladimir A; Zakharova, Irina O et al. (2012) Age-associated increase in salt sensitivity is accompanied by a shift in the atrial natriuretic peptide modulation of the effect of marinobufagenin on renal and vascular sodium pump. J Hypertens 30:1817-26
Haller, Steven T; Kennedy, David J; Shidyak, Amjad et al. (2012) Monoclonal antibody against marinobufagenin reverses cardiac fibrosis in rats with chronic renal failure. Am J Hypertens 25:690-6
Nikitina, Elena R; Mikhailov, Anton V; Nikandrova, Ekaterina S et al. (2011) In preeclampsia endogenous cardiotonic steroids induce vascular fibrosis and impair relaxation of umbilical arteries. J Hypertens 29:769-76
Fedorova, Olga V; Shapiro, Joseph I; Bagrov, Alexei Y (2010) Endogenous cardiotonic steroids and salt-sensitive hypertension. Biochim Biophys Acta 1802:1230-6

Showing the most recent 10 out of 12 publications